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With the way cleared for increased use of the fuel additive methylcyclopentadienyl manganese
tricarbonyl (MMT) in the United States, the issue of possible public health impacts associated
with this additive has gained greater attention. In assessing potential health risks of particulate
Mn emitted from the combustion of MMT in gasoline, the U.S. Environmental Protection Agency
not only considered the qualitative types of toxic effects associated with inhaled Mn, but
conducted extensive exposure-response analyses using various statistical approaches and also
estimated population exposure distributions of particulate Mn based on data from an exposure
study conducted in California when MMT was used in leaded gasoline. Because of limitations in
available data and the need to make several assumptions and extrapolations, the resulting risk
characterization had inherent uncertainties that made it impossible to estimate health risks in a
definitive or quantitative manner. To support an improved health risk characterization, further
investigation is needed in the areas of health effects, emission characterization, and exposure
analysis. Environ Health Perspect 106(Suppl 1):191-201 (1998). http.//ehpnet1.niehs.nih.gov/
docs/1998/Suppl-1/191-201Jdavis/abstract.html
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Introduction
Methylcyclopentadienyl manganese
tricarbonyl (MMT) is an organometallic
compound developed by the Ethyl
Corporation (Richmond, VA) in the 1950s
to increase the octane level ofgasoline and
thereby enhance the antiknock properties of
the fuel. It also was marketed to improve
the combustion offuel oil and turbine fuel
(1). Even before the introduction ofMMT
into the U.S. fuel supply began in 1976,
concerns were raised about its potential
public health implications (2). After passage
ofthe 1977 amendments to the Clean Air
Act (CAA) (3), however, the manganese
(Mn) additive was legal for use only in
leaded gasoline. According to the Ethyl
Corporation (4) over 70 million pounds of
MMT have been sold for use in U.S.
leaded gasoline since 1976. In 1979, while
crude oil was in short supply, the U.S.
Environmental Protection Agency (U.S.
EPA) also allowed MMT to be added to
unleaded gasoline for a few months. The
limited usage of MMT in leaded gasoline
was permitted until lead was phased out of
U.S. gasoline at the end of1995.
The Ethyl Corporation has applied to
the U.S. EPA several times since 1978 for
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permission to sell MMT for use in unleaded
gasoline. Section 21 1(f) of the CAA (3)
makes it unlawful for a manufacturer to
introduce any fuel or fuel additive (F/FA)
that is not substantially similar to F/FAs
used in the certification of 1975 or later
vehicle engines. This prohibition against
new F/FAs may be waived if an applicant
establishes that the F/FA will not cause
or contribute to an exceedance ofvehicle
emission standards. If the U.S. EPA
Administrator does not act to grant or
deny a waiver petition within 180 days of
receipt ofthe application, the statute pro-
vides that the waiver shall be automatically
granted. Four waiver petitions submitted
by the Ethyl Corporation were denied
because ofconcerns regarding increases in
exhaust hydrocarbon emissions resulting
from MMT use. During consideration of
the third and fourth applications, the U.S.
EPA also raised concerns regarding the
possible adverse health effects of an
increase in airborne Mn resulting from
MMT use. Ultimately, in July 1994, the
U.S. EPA Administrator denied the Ethyl
Corporation's waiver petition specifically
because of concerns about risks to public
health (5). In 1995, the Ethyl Corporation
successfully challenged the denial ofits peti-
tion in federal court (6). The court ruled
that Section 211(f)(4) ofthe CAA (3) pro-
vides no basis for U.S. EPA to deny Ethyl's
petition on any grounds except whether
MMTwould cause or contribute to a failure
ofanyemission control device or system.
In May 1994, as mandated in CAA (3)
Section 211(b) and (e), the U.S. EPA
issued the F/FA rule (7), which required
that F/FA manufacturers provide evidence
from existing studies or conduct new tests
to address specified health end points (i.e.,
at a minimum, subchronic inhalation toxi-
city studies that include reproductive and
developmental toxicity, neurotoxicity, and
mutagenicity end points). Under the F/FA
rule, manufacturers whose products were
not chemically similar to F/FAs previously
registered by the U.S. EPA could not mar-
ket their products until specified toxicity
and other information was provided to the
agency. Although the U.S. EPA main-
tained that MMT had not been previously
registered, the Ethyl Corporation success-
fully challenged that position as well (8).
Consequently, the Ethyl Corporation has
been marketing MMT to U.S. oil refineries
since December 1995. However, as pro-
vided by the F/FA rule, studies prescribed
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by the U.S. EPA must still be conducted
within a specified time frame even though
MMT is already in use.
The Canadian government has permit-
ted the use of MMT in gasoline in all
provinces since 1978 but recently banned
the importation of MMT, which could
effectively eliminate its use in Canadian
gasoline. The Ethyl Corporation indicated
that it would challenge the Canadian
importation ban under provisions of the
North America Free Trade Agreement (9).
Although MMT is apparently permitted in
Argentina, Australia, Russia, and condi-
tionally in New Zealand (10), whether it is
actually used in any countries apart from
the United States and Canada is unknown.
Because MMT is relatively inexpensive
as an octane enhancer, it could be in fairly
widespread use across the United States.
However, the 1990 CAA Amendments
(11) specifically prohibit the use of fuel
additives containing metals in areas desig-
nated for the use ofreformulated gasoline.
Except for such areas (including the entire
state of California, which specifically
banned MMT in 1991), MMT is legal for
use in most of the gasoline sold in the
United States. Moreover, other provisions
ofthe 1990 CAA Amendments (11) allow
the Ethyl Corporation to petition sepa-
rately for a waiver to market MMT even in
reformulated gasoline areas. Although sev-
eral major petroleum companies have indi-
cated that they would not add MMT to
their products, a large market may still
exist in the United States.
In formulating policy on the use of
MMT, particular caution has been exer-
cised because ofprevious experience with
adverse public health impacts associated
with extensive population exposure to a
heavy metal from a fuel additive in gaso-
line, namely tetraethyl lead (TEL) (12).
Blood lead levels in the U.S. population
correlate with changes over time in the use
ofTEL in gasoline, a fuel used pervasively
in the United States. This correlation is
compelling evidence of how a relatively
small concentration ofa fuel additive may
result in significant exposure ofthe general
population (13). In the case ofTEL in
gasoline, the primary exposure issue was
the combustion emissions ofparticulate
lead from vehicles, rather than the fuel
additive itself. As lead was emitted from
tail pipes and dispersed into the atmos-
phere, population exposures occurred pri-
marily by inhalation of particles in the
ambient air and secondarily from ingestion
ofthese particles deposited on food, soil,
and other surfaces with which the entire
population or particular subpopulations
(e.g., young children) came into contact. As
with TEL the U.S. EPA assessment ofthe
potential health risks associated with MMT
was concerned primarily with combustion
emissions from vehicles, not the fuel addi-
tive itself. Given that the allowable concen-
tration of MMT in U.S. fuel is only 1/32
(0.031) g Mn/gal ofgasoline and that the
compound undergoes rapid photodegrada-
tion in the atmosphere (14), MMT itself
was not considered a significant exposure
risk for the general population, except for
accidental or occupational contacts.
Unlike lead, the oral route ofexposure
is considered less of a threat with Mn.
Dietary Mn has relatively low toxicity at
most exposure levels due in part to a low
rate ofabsorption from the gastrointestinal
tract and in part to efficient regulation by
homeostatic mechanisms (15). The Mn
oral reference dose (RfD) is 0.14 mg/kg/day
for dietary sources. However, for nondi-
etary sources such as water or soil and
especially for infants consuming formula
prepared with water, a value of 0.05
mg/kg/day is specified by the U.S. EPA
(15). The Mn RfD reflects the fact that
Mn is considered a nutritionally essential
trace element; it is required for enzymes
such as hydrolases, kinases, decarboxylases,
and transferases, and for metalloenzymes
such as mitochondrial superoxide dismu-
tase, which are important for normal func-
tioning of the central nervous system
(CNS) and other systems. However, Mn
toxicity to workers exposed by inhalation
has been recognized since the early 1800s
(16). Unlike ingested Mn, inhaled Mn is
transported directly from the respiratory
tract to the brain before its first pass by the
liver. Depending on the form of Mn
inhaled, its conversion to other oxidation
states (e.g., oxidation ofMn2+ to Mn3+ or
reduction ofMn4+ to Mn3+), and its ability
to enter the brain through a protein trans-
port mechanism or otherwise (17-19), a
significant fraction of inhaled Mn may
reach target sites in the CNS, especially the
basal ganglia. Some evidence indicates that
uptake may occur via the nasal mucosa,
with direct olfactory axonal transport
to the CNS (20), as well as via alveolar
absorption into the bloodstream.
According to an early report from the
Ethyl Corporation (21), the combustion of
MMT in gasoline produces submicron par-
ticles ofMn tetraoxide (Mn304), which
contains both Mn2+ and Mn3+. More
recent analyses provided to the U.S. EPA
by the Ethyl Corporation indicate the
presence of a Mn phosphate compound
containing only Mn2+. At this writing, the
form or forms of Mn produced by com-
bustion ofMMT in gasoline have not been
definitively ascertained.
U.S. EPA Health Risk
Assessment of MMT
The evaluation ofthe potential health risks
associated with the use of MMT in
unleaded gasoline followed the National
Research Council paradigm ofidentifying
the types ofhealth hazards, characterizing
the exposure-response relationship, and
relating this information to a human expo-
sure assessment (22). Because very little
information was available on the inhalation
toxicity ofMn304, thought to be the pri-
mary combustion product of MMT in
gasoline, the U.S. EPA assessment of
MMT (23) considered inhalation data on
any form ofMn. Most ofthis information
came from studies ofoccupational popula-
tions and from some laboratory animal
experiments. Primary features ofexcessive
occupational exposure to Mn include neu-
robehavioral, respiratory, and reproductive
effects. Manganism is characterized byvari-
ous psychiatric and movement disorders
and usually consists oftwo or three phases
(24). The first is a psychiatric aspect that
includes disturbances such as excessive
weeping and laughing, sleep disturbances,
irritability, apathy, and anorexia. The term
manganese madness (locura manganica) is
sometimes applied to these symptoms of
Mn toxicity (25). A second phase consists
ofneurologic and neuromuscular signs such
as gait disturbances, dysarthria, dumsiness,
muscle cramps, intention tremor, and
masklike facial expressions. In addition a
final stage ofMn intoxication may involve
symptoms of irreversible dystonia and
hyperflexion of muscles that may not
appear until many years after the onset of
exposure (25). Similarities between the
later stages ofmanganism and Parkinson's
disease have been noted frequently because
of the impairment offine motor control,
lack of facial expression, and apparent
involvement ofunderlying common neu-
roanatomical and neurochemical factors
(26,27). However, most clinical neurolo-
gists now differentiate, both functionally
and neuroanatomically, between the two
afflictions oftheextrapyramidal tracts (28).
The precise mechanisms of Mn
neurotoxicity are not well understood, but
it appears that Mn can affect several differ-
ent aspects ofCNS structure and function.
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Postmortem examinations ofMn-exposed
humans and experimental studies of Mn-
exposed laboratory animals indicate that
Mn is distributed preferentially to nuclei of
the basal ganglia, particularly the caudate,
putamen, globus pallidus, subthalamic
nucleus, and substantia nigra, and to a
lesser extent to other regions of the brain,
including the cerebellum and pituitary
(29-31). Generally the primary sites of
neuropathologic changes associated with
Mn toxicity in humans and experimental
animals are the basal ganglia, particularly
the globus pallidus, caudate, and putamen.
There is little or no involvement of the
substantia nigra (29-33). Investigation of
the mechanisms of Mn neurotoxicity has
focused on the oxidative properties ofMn
(especially Mn3+) and its interactions with
the dopaminergic system, including bipha-
sic increases and decreases in dopamine
levels associated with Mn exposure (34).
The role of nigrostriatal pathways and
dopaminergic and y-aminobutyric neurons
in Mn neurotoxicity has not been fully
established; some evidence suggests that
the nigrostriatal pathway itself remains
intact, with damage occurring postsynapti-
cally (31,35). Mitochondrial uptake and
disruption have also been investigated as
mechanisms ofMn neurotoxicity (36,37).
Other organs and systems are also
targets of Mn toxicity. Respiratory effects
such as pneumonia, susceptibility to acute
infections of the respiratory tract, and
cough have been noted in Mn workers
(38,39). One study has suggested a possi-
ble increase in prevalence ofrespiratory ill-
nesses in school children residing near a
point source ofatmospheric Mn pollution
(40). Occupational case reports frequently
indicate that reproductive function may be
impaired by Mn exposure, often mani-
fested by symptoms such as loss oflibido,
impotence, and similar complaints (24,41).
Lauwerys et al. (42) reported a statisti-
cally significant decrease in the number
of children born to workers exposed to
Mn dust during the ages of 16 to 25 and
26 to 35 years, as compared to control
workers. Disturbance of the hypothala-
mic-pituitary-gonadal axis hormones has
been implicated in Mn toxicity by other
investigators (43).
In addressing carcinogenic effects the
U.S. EPA placed Mn in a Group D weight-
of-evidence category, which signified that
it was not classifiable as to human carcino-
genicity because ofmixed or insufficient
evidence (44). Given this fact, together
with the more extensive database on the
neurobehavioral effects of Mn and some
indications that respiratory and reproduc-
tive systems may not be as sensitive to Mn
exposure as is the CNS (45), the U.S. EPA
health assessment focused on the potential
for chronic noncancer effects, particularly
neurotoxic effects.
The exposure-response aspect of the
assessment consisted ofthe inhalation ref-
erence concentration (RfC) for Mn. The
RfC is an estimate (with uncertainty span-
ning about one order ofmagnitude) of a
continuous inhalation exposure level for
the human population (including sensitive
subpopulations) that is likely to be without
appreciable risk ofdeleterious noncancer
effects during a lifetime. In 1990 the U.S.
EPA issued an RfC for Mn of0.4 pg/m3
(46). As additional information and pub-
lished studies became available in the
course ofreconsidering the waiver petition
for MMT, the RfC was revised in 1993
(47) and incorporated into a reevaluation
of the potential inhalation health risks
associated with MMT (23).
InhalatonReference
Concentration forManganese
The 1993 RfC for Mn (47) was based
primarily on a study ofMn-exposed alka-
line-battery plant workers in Belgium by
Roels et al. (45). This cross-sectional study
evaluated neurobehavioral and other end
points in 92 male workers exposed to Mn
dioxide (MnO2) dust, compared to a
matched control group of 101 male work-
ers without industrial Mn exposure. The
geometric mean occupational-lifetime inte-
grated respirable fraction ofparticulate mat-
ter (PM5) (subscript number indicates
particle size in pm) dust concentration was
793 pg Mn/m3xyears (range: 40-4,433).
The Mn-exposed workers performed signif-
icantly worse than matched controls on sev-
eral measures ofneurobehavioral function,
particularly tests ofeye-hand coordination,
hand steadiness, andvisual reaction time.
Similar neurobehavioral impairments
were also found in an earlier studyby Roels
et al. (39) ofa different occupational pop-
ulation in Belgium exposed to comparable
(total dust) concentrations of mixed Mn
oxides and salts. In addition, a study of
Canadian workers by Mergler et al. (48)
indicated that compared to matched con-
trols, performances on tests ofrapid alter-
nating hand movements, hand steadiness,
and other aspects of fine motor control
were significantly worse in workers who
had been exposed to even lower concentra-
tions of respirable Mn dust than those
measured by Roels et al. (45). However,
information on past exposure levels was
notprovided byMergler et al. (48). Reports
of a Swedish study ofMn-exposed steel
workers (49) also have provided evidence
of comparable neurobehavioral impair-
ments, including slower reaction time and
finger-tapping speed. Collectively these
studies, now complemented by more
recent work (50), constitute compelling
evidence of neurotoxicity associated with
low-level occupational Mn exposure
below the then-current threshold limit
value (TLV) of 5 mg/m3. [The American
Conference of Governmental Industrial
Hygienists (51) has since revised the
TLV to 0.2 mg/m3.] The fact that the
speed and coordination of motor func-
tion are especially impaired is noteworthy
because of the consistency with the other
epidemiologic, clinical, and experimental
animal evidence ofneurotoxicity at higher
concentrations ofMn (47).
In deriving an RfC for- Mn, the
geometric mean integrated respirable dust
concentration (793 pg Mn/m3x years)
from Roels et al. (45) was divided by the
average period ofworker exposure (5.3
years) to eliminate time (in years) from the
time-weighted average, thereby yielding a
lowest observed adverse effect level (LOAEL)
of 150 pg Mn/m3. Other adjustments made
to relate the occupational exposure (e.g., 5
days/lOm3 air breathed per week, day) to
lifetime environmental exposure (7
days/20m3 air breathed per day) produced
an exposure-adjusted LOAEL of 50 pg
Mn/m3. This value was then divided by a
total uncertainty factor of 1000 to yield an
RfC of0.05 pg/m3. The total uncertainty
factor of 1000 incorporated the following
factors: 10 to protect sensitive individuals
(e.g., infants, pregnant women, elderly), 10
for using an LOAEL in lieu of a no
observed adverse effect level (NOAEL), and
a composite factor of 10 for database limita-
tions. The composite factor subsumed three
areas ofuncertainty: extrapolation from sub-
chronic to chronic exposure, inadequate
reproductive and developmental data,
and unknown differences in the toxicity of
different forms ofMn.
After the U.S. EPA issued the RfC for
Mn in 1993 (47), the Ethyl Corporation
requested that the U.S. EPA consider alter-
native approaches to analyzing the data of
Roels et al. (45) and including supplemen-
tary data provided by Roels (52). One
objective ofsuch analyses was to identify
an NOAEL and thereby eliminate or
reduce one uncertainty factor of 10 in the
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derivation ofthe RfC. In response U.S.
EPAscientists applied avarietyofstatistical
approaches proposed by Ethyl or under
consideration by the U.S. EPA, including
benchmark dose analyses of the type
described by Crump (53) and Bayesian
analyses of the type described by
Hasselblad and Jarabek (54). With several
choices of exposure measures, effects
measures, exposure-response models, and
uncertainty factors, more than 100 RfC
estimates were obtained by applying vari-
ous statistical methods. Ofthese the most
plausible estimates for alternatives to the
Mn RfC of 0.05 jig/m3 ranged from
approximately 0.09 to 0.2 pg/m3 (23,55).
ExposureAssssment
Although ambient air levels may provide a
first step in attempting to assess human
exposure to particulate Mn, personal expo-
sure levels ofautomotive-source pollutants
may be uncorrelated with or underesti-
mated by ambient air levels (56). Data on
personal exposure levels ofMn likely to be
associated with the use of MMT as an
additive in unleaded gasoline have been
limited. Some studies (57,58) of small
samples oftaxi drivers, garage workers, and
office workers/commuters were conducted
in Canada, where the allowable MMT
concentration in gasoline was 1/16 (0.062)
g Mn/gal. [Although as much as 1/16 g
Mn/gal was permitted in Canada, the con-
centration actually used was probably
closer to the U.S. limit of 1/32 (0.031) g
Mn/gal (59).] These studies had inade-
quate sample sizes and lacked probabilistic
statistical designs that would help ensure
the representativeness ofthe sampled indi-
viduals. Moreover, meteorologic and other
factors that might have affected ambient
air Mn measurements over the relatively
short time periods ofthese studies (1 to 2
weeks at most) were not adequately charac-
terized. Because of limitations such as
these, no quantitative assessment ofper-
sonal exposures to Mn in a Canadian pop-
ulation was possible. However, some
studies (60) have clearly indicated a gen-
eral relationship between personal expo-
sure levels of Mn and proximity to
vehicular emissions ofcombusted MMT.
Thus populations living near high traffic-
volume areas, for example, would be
expected to experience higher Mn exposure
levels (61).
The only published study that has used
a probability-based representative sampling
design for evaluating exposure levels ofMn
in a general population was the particle
total exposure assessment methodology
(PTEAM) study (62). Although this study
was not conducted with a particular focus
on either Mn or MMT, it provided valu-
able information on potential Mn expo-
sure associated with MMT use because
MMT was an additive in leaded gasoline in
California prior to and during the period
of the PTEAM study. The study was
conducted in Riverside, California, over a
7-week period in the fall of 1990 and used
personal and stationary monitors to mea-
sure Mn concentrations indoors and out-
doors. Of the 139,000 nonsmoking
residents 10 years of age and older in
Riverside, 178 individuals were selected
through a stratified sampling plan to repre-
sent the general population and were mon-
itored over two 12-hr periods (daytime and
nighttime). More than 2750 air samples of
particles were collected.
In the PTEAM study, measurements of
personal exposure levels ofPM1o Mn indi-
cated that approximately halfofthe popula-
tion in Riverside in the study period had
24-hr personal exposures to PM1o Mn
exceeding 0.035 pg/m3, with the highest
1% of the population having exposures
above 0.22 pg/m3 PM1o Mn. However,
because the RfC for Mn was based on PM5
dust measurements in the study ofRoels et
al. (45), it was preferable to consider a pop-
ulation distribution ofpersonal exposure
levels of PM5 Mn to more closely relate
exposure and effect metrics. In addition it
was necessary to project from the situation
in Riverside around the time ofthe PTEAM
study (when leaded MMT gasoline consti-
tuted about 14% ofthe gasoline sold and
contained an average of0.048 g Mn/gal) to
a future scenario that assumed 100% ofthe
unleaded gasoline would contain MMT at
1/32 (0.031) gMn/gal.
The derivation of the projected
exposure estimates involved several steps
and extrapolations (23) to yield two pro-
jections of long-term personal exposure
levels of PM4 Mn (the nearest approxi-
mation possible to PM5) in relation to
MMT usage at 1/32 g Mn/gal in 100% of
unleaded gasoline. Albeit long term, these
projections were limited to the fall season
and could not be considered estimates of
annual average exposure levels. Two esti-
mates are presented because alternative
approaches were employed to relate
PM2.5 measurements from stationary
indoor monitors to PM4 personal expo-
sure levels. In essence it was estimated
that half of the population could experi-
ence PM4 Mn exposure levels of greater
than approximately 0.045 to 0.050 pg/mi3.
Also, based on the two projection esti-
mates, approximately 5 to 10% ofthe pop-
ulation could have personal exposure levels
around 0.1 pg/m3 PM4 Mn or higher, with
the highest 1% above 0.15 pg/m3.
Note that these projections refer
specifically to Riverside, California, but are
probably reasonably representative ofthe
greater Los Angeles metropolitan area
(population > 14.5 million). Although the
Riverside-based estimates cannot be
applied quantitatively to any other U.S.
metropolitan areas, the projections may
have some relevance to other U.S. cities or
locales (e.g., in the Southwest) that qualita-
tively resemble Riverside in meteorology,
traffic patterns, and other characteristics of
relevance to automotive Mn levels. The
presence ofa major point source or sources
of Mn in a community (not a factor in
Riverside) would also add some increment
to the level ofMn exposure experienced by
persons in that community. Possibly, then,
several hundreds ofthousands ofindividu-
als could be exposed to PM4 Mn levels of
approximately 0.1 pg/m3 or higher if
MMT were used in 100% ofthe unleaded
gasoline at 1/32 g Mn/gal in all of these
areas. However, it must be emphasized that
because ofthe limited available exposure
data, a great deal ofuncertainty surrounds
such estimates. The actual exposure levels
could be much higher or lower.
RiskCharacterization
To assess health risks, qualitative and quan-
titative health effects information must be
related to available exposure information.
From the standpoint ofa qualitative hazard
identification, the available evidence amply
demonstrates that inhaled Mn is toxic to the
nervous system, the respiratory system, and
the male reproductive system. Although
occupational epidemiologic findings of
impaired motor function (e.g., reductions in
eye-hand coordination, slower hand or fin-
ger movements, and less control offine
movement) may be subde and probably not
readily evident to clinical physicians, they
are nevertheless significant from a public
health standpoint when considered as
potential population effects.
Quantitative dose-response analyses of
such neurobehavioral data support a range
ofapproximately 0.09 to 0.2 pg/m3 as pos-
sible alternatives to the value of0.05 pg/m3
that was established as the Mn RfC in
1993 and remains as such on the U.S. EPA
Integrated Risk Information System data-
base (47). By definition RfC analyses do
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not yield a precise concentration that
defines a demarcation between safety and
hazard. Rather, interpretation ofa Mn RfC
estimate is best made in relation to an
assessment ofpopulation exposures to Mn,
with the understanding that the RfC is a
protective level, not a predictive value.
The exposure assessment provides
reasonable but necessarily uncertain esti-
mates ofpersonal exposure levels ofMn that
might result from the use ofMMT in gaso-
line. These estimates indicate that ifMMT
(at 1/32 gMn/gal) were used in all unleaded
gasoline in Riverside, California, approxi-
mately 40 to 50% ofthe population could
experience PM4 Mn exposures exceeding
the 1993 RfC of0.05 ,ug/m3 (derived from
PM5 Mn health effects data) and approxi-
mately 5 to 10% could experience PM4 Mn
exposure levels around 0.1 pg/m3 orhigher.
Figure 1 juxtaposes projected personal
exposure distributions and selected RfC
values. It is evident that some candidate
RfC estimates as well as the 1993 verified
RfC are in the range ofthe exposure esti-
mates. Exceeding the RfC does not neces-
sarily indicate that a public health risk
exists. With orders ofmagnitude separating
an LOAEL or NOAEL from the RfC, it is
impossible to state whether projected expo-
sures above the RfC would lie above or
below a presumed threshold level for
adverse health effects on the actual concen-
tration-response curve for Mn neurotoxic-
ity. Obviously, however, this inability to
state definitively that adverse health effects
will occur cannot be interpreted to imply
that no health risk exists at exposure levels
C-
0.1
0.01
* * 0
000*
1993 verified RfC Alternative RfC Exposure
estimates estimates
assuming
100% MMT
usage
Figure 1. Comparison of Mn RfC values and projected
distributions of personal exposure levels of Mn. Two
exposure distributions are collapsed into a single verti-
cal line, with the median of each distribution repre-
sented by a horizontal mark.
exceeding the RfC. In short, although it is
not possible to quantify an estimation of
risk, a reasonable basis exists for concern
regarding potential public health risks,
especially for susceptible subpopulations, if
MMT is used widely in unleaded gasoline.
For a more definitive estimate ofrisk, it is
essential that more information be obtained
on exposure to and health effects of Mn
combustion products ofMMT in gasoline.
Uncertainties
Uncertainties are inherent in any risk
assessment. In the case ofthe MMT assess-
ment, both the exposure-response analyses
and the exposure assessment contain
assumptions, extrapolations, and judg-
ments, each ofwhich introduces uncertain-
ties to the risk characterization. In the RfC
analyses uncertainties are formally repre-
sented by numerical uncertainty factors, as
well as by the fact that, by definition, an
RfC reflects uncertainty spanning perhaps
an order ofmagnitude. RfCs are designed
to be more protective (i.e., lower) when
there is a greater number or degree of
uncertainties orinformation gaps.
These uncertainties require elaboration
ifthey are to be appreciated as more than
semiquantitative representations of con-
cerns. An uncertainty factor of 10 for pro-
tection ofsensitive individuals is commonly
applied in deriving RfCs, particularly from
epidemiologic data limited to healthy adult
workers. Susceptible subpopulations may
have an increased potential for excessive
Mn body burdens attributable to increased
absorption or altered clearance mecha-
nisms, as suggested bylimited data on chil-
dren (63,64), pregnant women (65,66),
elderly persons (67), iron- or calcium-defi-
cient individuals (18,68,69), and individu-
als with liver impairment (70,71).
Children are ofspecial concern for several
reasons. As the long-term or irreversible
effects ofexposure to lead and other devel-
opmental neurotoxicants during certain
critical stages ofdevelopment have illus-
trated (72), Mn exposure during a limited
period of early development might be
capable of inducing permanent or irre-
versible damage to the developing CNS.
Recent work comparing the neurotoxic
effects of Mn in rats at different ages
(73,74) supports a concern about greater
sensitivity to Mn neurotoxicity during
early development. Moreover, several
studies (43,75-77) have demonstrated
alterations in dopamine levels in young
mice and rats exposed to Mn via nonin-
halation routes during early postnatal
development. Such findings raise concerns
about the potential for adverse impacts on
children. Young children could also be at
higher risk because ofmetabolic differences,
as suggested by the fact that homeostatic
mechanisms for regulating Mn absorption
and elimination are not well developed in
infants (63,78,79).
The elderly are another special popula-
tion ofconcern. At least one report ofsub-
chronic Mn poisoning in humans via the
oral route points to a greater vulnerability
of the elderly (67). Also, over time Mn
body burdens and/or small impairments in
neurobehavioral function may accumulate.
Ifneurobehavioral function is already com-
promised by normal aging processes or dis-
ease states (e.g., preclinical Parkinsonism),
the ability to compensate for declines in
neurobehavioral function could be eventu-
ally overwhelmed by additional, albeit pos-
sibly quite small, insults attributable to Mn
(80,81). Note that Parkinson's disease is
typically a geriatric disease in which symp-
toms are seen only when the loss ofbrain
cells that produce dopamine (the loss of
which may also be involved in Mn toxicity)
reaches 80% or more. IfMn were to con-
tribute to such losses, the effect could be a
more severe or earlier onset of declining
function in senescence (82,83).
Recent epidemiologic studies of
occupational cohorts do litde to reduce this
concern because ofthe relativelyyoungpop-
ulations studied. The oldest worker in the
study by Roels et al. (45) was less than 50
years of age and the average age in that
study was only 31.3 years. Average worker
ages in other keystudies were also low: 34.3
(39), 43.4 (48), and 46.4 (49) years ofage.
Ifthe elderlyactuallyare moresusceptible to
even subtle manifestations ofMn toxicity,
the implications for reduced function and
consequent increases in societal healthcare
costs could be enormous.
Individual differences in susceptibility to
Mn toxicity have long been apparent in the
occupational medicine literature (68,84).
The U.S. EPA assessment ofMMT noted
that individual data for two workers in the
study by Roels et al. (45) suggested that
they may have been especially susceptible
to the neurobehavioral effects ofoccupa-
tional Mn exposure as reflected by their
abnormal scores and limited exposure dura-
tions. Attempts to fit an exposure-response
model to the Roels (52) data with these
two subjects included resulted in asupralin-
ear curve (55). One of the difficulties in
investigating such individual differences
in worker populations is that inherently
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susceptible individuals would probably be
more likely to change to other types of
employment, which leaves a greater propor-
tion ofrelatively less sensitive individuals
among the Mn workerpopulation.
Another concern identified in deriving
the Mn RfC included the lack ofchronic
exposure data. In the 1992 Belgian study
(45) the mean period ofexposure was only
5.3 years (range: 0.2 to 17.7 years), with a
marginally longer exposure of7.1 years
in the earlier Belgian study (39). In the
Swedish (49) and Canadian (48) studies
the mean durations ofexposure were some-
what longer: 9.9 and 16.7 years. It is quite
possible that longer exposure periods or
testing ofolder workers might result in the
detection ofeffects at lower concentrations
than is possible after shorter periods of
exposure or in younger workers. On the
other hand it is also evident from these
studies that a relatively short period of
occupational Mn exposure may be suffi-
cient to induce Mn neurotoxicity. A related
concern is that some manifestations ofMn
toxicity may become evident only after a
considerable lag, possibly several years after
exposure occurred or terminated (24,25).
An uncertainty factor for extrapolation
from a subchronic exposure to chronic expo-
sure was included in deriving the Mn RfC
estimates. However, a halffactor ofonly 3
(on a base 10 logarithmic scale) was used for
this area ofuncertainty. Ifthe average period
ofMn exposure (4 years geometric mean) in
the Roels et al. study (45) is compared to an
assumed lifetime of70 years, one could
argue that a factor of70/4= 17.5, or at least
10, would be a more appropriate adjust-
ment for subchronic to chronic exposures.
In general the U.S. EPA has used an uncer-
tainty factor of3 for subchronic-to-chronic
extrapolation for other chemicals with com-
parable databases. It may be fair to say,
however, that in this instance a factor of3
probablydid noterr in thedirection ofbeing
too conservative (protective).
Also reflected in the composite
uncertainty factor of 10 is the lack ofade-
quate data on reproductive and develop-
mental effects. No known studies have
investigated human female reproductive
function, and male worker reproductive
function has not been extensively investi-
gated even though it is affected by Mn
exposure (42). Also, limited information
suggests the possibility that prenatal expo-
sure oflaboratory rodents to MnO2 (via
the inhalation exposure ofpregnant dams)
may depress neurobehavioral activity in
neonatal rats, with continuing postnatal
exposure of the pups possibly intensifying
this depression (85). Thus the potential for
developmental toxicity attributable to pre-
natal Mn exposure exists, although the
minimal concentrations and durations of
exposure sufficient to induce such effects
are not known.
Another aspect of the composite
uncertainty factor is the fact that different
forms of metals may have different toxic
properties. For example different oxidation
states ofcertain metals (e.g., chromium,
nickel, mercury) have different toxicities,
and some researchers have suggested that
different oxidation states ofMn may have
quite different roles in Mn neurotoxicity
(86,87). There are indications that the
higher valence states ofMn (Mn+3, Mn+4)
and the higher oxides in ores (Mn203 and
Mn304) are more toxic (88,89). At pre-
sent, however, insufficient information
exists by which to determine the relative
toxicities ofdifferent species ofMn.
Bioavailability may also figure into
differences in the effects ofdifferent forms
of Mn. In their 1992 report Roels et al.
(45) noted that geometric mean blood and
urinary Mn levels ofworkers exposed only
to MnO2 were lower than those ofworkers
exposed to mixed oxides and salts in their
1987 report (39) even though airborne
total dust levels were approximately the
same. Mena et al. (68) observed no differ-
ence between the absorption of 1-pm parti-
cles ofMn chloride (MnCl2) and Mn203
in healthy adults. Drown et al. (90) found
that following intratracheal instillation of
MnCl2 and Mn304 in rats, the water-solu-
ble chloride cleared four times faster than
the insoluble oxide from the respiratory
tract. However, despite this initial differ-
ence, after 2 weeks the amounts oflabeled
Mn in the respiratory tract were similar for
the two compounds. Recent work by
Komura and Sakamoto (91) comparing
different forms ofMn in diet suggested that
less water-soluble forms such as MnO2 were
taken up to a significantly greater degree in
cerebral cortex ofmice than the more solu-
ble forms of MnCI2 and Mn acetate
(Mn[CH3COO]2). However, the corpus
striatal binding characteristics of the +4
valence state ofMn in MnO2 were not sub-
stantially different from those ofthe diva-
lent forms in MnCl2, Mn(CH3COO)2,
and Mn carbonate.
Recent experimental work by Roels et
al. (92) provides additional evidence on
differences in bioavailability ofdifferent
forms ofMn. Although MnCl2 and MnO2
were both bioavailable by the respiratory
tract in rats, the uptake of MnCl2 was
significantly greater than that of MnO2,
as reflected in striatal concentrations.
Moreover, MnO2 given orallyproduced no
significant increase in blood or cerebral tis-
sue Mn concentrations, in contrast to
approximately 70% increases over controls
in rats given MnCI2 by either gavage or
intratracheal instillation. Once absorbed,
the ability of Mn to cross the blood-brain
barrier and the toxicity produced in brain
regions may be a function ofthe oxidation
state ofMn (86,87). In the case ofMn304,
both divalent and trivalent forms ofMn are
present. At this time considerable uncer-
tainty accompanies any attempt to extrapo-
late from toxicity data on MnO2 or MnCI2
to the yet-to-be-determined form(s) ofMn
produced by combustion ofMMT in gaso-
line. Because insufficient data are available
on the toxicologic and pharmacokinetic
properties ofvarious compounds ofMn, for
the purposes of deriving an RfC for Mn
no distinction was made between various
compounds ofMn (47).
Further uncertainties come into play as
the Mn RfC is used as part ofthe risk char-
acterization related to MMT. Some of
these issues have been intensively examined
in an exchange ofcomments between the
Ethyl Corporation and the U.S. EPA in
conjunction with preparation ofthe MMT
assessment (93). One rather fundamental
issue concerns the relative toxicity of Mn
by oral and inhalation routes. The Ethyl
Corporation has questioned the biological
plausibility ofthe RfC because it implies a
roughly 100-fold difference in systemic
dose from what would be associated with
the oral RfD for Mn. Several points could
be made about such comparisons, but a
key point here is that delivered dose, not
systemic dose, is critical, i.e., how much
Mn actually reaches and enters a target
organ such as the basal ganglia. The recent
report of Roels et al. (92) clearly demon-
strates that rats treated with either MnCl2
or MnO2 had significantly greater concen-
trations ofMn in the striatal region ofthe
brain when the compounds were adminis-
tered by intratracheal instillation than by
gavage, despite the fact that the oral dose
was 20-fold greater than the inhalation
dose and produced comparable steady-state
blood Mn concentrations. These findings
reinforce concerns about the risks ofMn
dispersed through ambient air.
Clinical and other evidence also suggests
qualitative concerns that are difficult to
measure quantitatively or demonstrate with
currently available methods. Specifically,
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much ofthe clinical literature on manganism
refers to a psychiatric component ofthe ill-
ness that often involves striking emotional
or mood changes that tend to appear
before changes in motor function are evi-
dent. Some more recent investigations (94)
suggest that aggressive behavior may be
associated with Mn exposure (as reflected
in the concentration of Mn in hair of
prison inmates). However, these reports
require substantiation by further studies,
and the validity and relevance ofhair Mn
levels as an indicator ofenvironmental Mn
exposure remains to be established.
The exposure assessment was built on
the PTEAM study (62). Given the strong
design and quality assurance features of
this study, it is reasonable to place a high
degree ofconfidence in the PTEAM data
as accurately representing 24-hr average
Mn exposure concentrations for the
Riverside population in the fall of 1990.
The major uncertainties in the exposure
assessment arise with the projections from
these data. In essence the assessment extrap-
olated from PM1o Mn personal exposure
data for a 24-hr period in the fall of 1990,
when MMT was used in about 14% of
gasoline at approximately 0.048 g Mn/gal,
to an estimate oflong-term PM4 Mn per-
sonal exposure levels in 1995, with MMT
assumed to be used in 100% ofgasoline at
0.031 g Mn/gal. Several points ofextrapo-
lation are evident: particle size (PM1o to
PM4), which in turn was to be related to
PM5 health data; sampling period (24 hr to
long-term or chronic exposure); season (no
extrapolation was possible beyond the fall);
past to future (1990 to 1995); extent of
usage (14 to 100%); and concentration in
fuel (0.048 to 0.031 g Mn/gal). Each of
these extrapolations required inferences, pro-
jections, estimation procedures, or judg-
ments. Although the intermediate steps
required to reach these estimates are not
described in detail here, it should be self-evi-
dent that, however reasonable and scientifi-
cally defensible these extrapolations may be,
they inherently introduce uncertainties into
the resulting exposure estimates. Given other
approaches or assumptions, rather different
projection estimates couldhave resulted.
Another major uncertainty for the
exposure assessment concerns the relation-
ship of these projections based specifically
on Riverside, California, to other commu-
nities. The PTEAM study itselfwas, strictly
speaking, designed to statistically represent
Riverside. Nevertheless Riverside probably
provides a reasonable representation ofthe
Los Angeles basin, given the commonalities
in geography, vehicle usage, and meteorol-
ogy. However the relevance ofthe Riverside
data to other U.S. communities presum-
ably depends on similarities or differences
in certain characteristics such as traffic den-
sity and meteorologic conditions. Riverside
County has approximately 9 billion vehicle
miles traveled (VMT) per year. Excluding
the other three counties in the Los Angeles
basin, about 19 other counties in the United
States have higher VMT levels than
Riverside. In the southwest United States, for
example, Phoenix (Maricopa County),
Arizona, has somewhat similar meteorologic
conditions and roughly double the VMT lev-
els ofRiverside. Houston (Harris County),
Texas, has about three times the VMT levels
ofRiverside. Notwithstanding these compar-
isons it remains to bedeterminedwhether the
Riverside-based estimates can be applied
quantitatively to any other U.S. metropolitan
area. It must therefore be emphasized that the
exposure assessment aspect ofthe MMT risk
characterization is highly uncertain in its
applicability to the broader U.S. population.
Research Directions
On 12 March 1991 the U.S. EPA and the
National Institute ofEnvironmental Health
Sciences jointly sponsored an international
symposium on health and exposure issues
related to Mn and MMT, followed by a
workshop on 13-15 March, which was
attended by more than 100 experts in the
fields ofexposure and health sciences (95).
The discussions in this workshop provided
useful input to U.S. EPA scientists as they
developed a program ofstudies that would
provide information needed to support an
improved, quantitative assessment of the
potential risks to public health associated
with MMT (96). Although the identifica-
tion of these information needs preceded
the reevaluation that figured into the 1994
U.S. EPA denial ofthe waiver petition by
the Ethyl Corporation, the needs have
remained largely unchanged since 1991.
Under health effects a major part ofthe
rationale for the program ofstudies cond-
sidered most needed was the premise that
Mn304 was the predominant form ofMn
to which human populations would be
exposed in conjunction with MMT usage.
The intent was to have studies performed
that would serve as a basis for deriving an
RfC specifically for Mn304, with the
uncertainty factors reduced as much as pos-
sible to increase the precision of the RfC.
The studies were to be designed to deter-
mine LOAELs and NOAELs for neurotoxi-
cologic, reproductive, developmental, and
respiratory effects ofinhaled Mn304. They
were to be conducted with rodents and,
particularly in the case ofneurotoxicologic
effects, nonhuman primates. In addition
the studies were intended to improve
knowledge ofsensitive subpopulations and
provide information on Mn bioaccumula-
tion to enable better extrapolation from
subchronic to chronic effects.
Primary emphasis was placed on the use
ofexperimental animal models rather than
on human epidemiologic studies. The
choice of animal models for Mn toxicity
depends on the end point of interest. For
respiratory effects rats (and to some extent
mice) are sensitive to Mn by inhalation and
other routes (97-100). Similarly, nonhu-
man primates have shown respiratory effects
in relation to inhaled particulate Mn (100).
Although reproductive effects ofingested
Mn have been evaluated in rats (101), it
appears that no rodent studies have investi-
gated reproductive end points with inhaled
Mn. However, there is no reason to believe
that rodents would not serve as an adequate
animal model for examining reproductive
effects ofMn by inhalation. Indeed, repro-
ductive assays using rats are specified for
standard testing of F/FAs under the F/FA
Rule issued by U.S. EPA (7).
For neurotoxicologic end points the
choice ofanimal model is more problem-
atic. Although rodents have shown neuro-
chemical alterations after Mn exposure by
inhalation (85) and noninhalation routes
(43,75-77), they appear less likely to show
behavioral effects at the same exposure lev-
els (102). Primates, however, appear more
sensitive to the neurotoxic effects ofMn,
including disturbances of behavior and
motor function (30,32,103,104). Some
speculation has suggested that the differ-
ence in neurobehavioral sensitivity of
rodents and primates may be related to the
fact that, unlike primates, rodents do not
have pigmented substantia nigra, which is a
brain region ofrelatively high Mn uptake.
However, it appears that other nuclei of
the basal ganglia are more likely to be tar-
get sites of Mn neurotoxicity (29). Thus
the choice of rodents or nonhuman pri-
mates for an animal model ofMn neuro-
toxicity should be guided in large part by
the type of neurotoxicologic end point
(e.g., neurochemical or neuropathologic vs
neurobehavioral) to be evaluated.
Epidemiologic studies of potentially
susceptible subpopulations chronically
exposed predominandy to the species ofMn
produced from MMTwould be ideal, iffea-
sible. However, even ifsuch a population
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could be identified (e.g., children or the
elderly living in a Canadian city with sub-
stantial vehicular traffic), characterizing
their inhalation and total exposure accu-
rately would be difficult. Although group
averages of urinary and blood Mn levels
have been suggested to reflect very recent
exposures and longer term body burden,
respectively (105), a suitable bioindicator
of Mn exposure that can differentiate
inhalation exposure from oral intake does
not exist (106). Magnetic resonance imag-
ing and positron emission tomography
techniques may offer a means ofinvestigat-
ing the distribution ofMn in vivoand eval-
uating the integrity of function of likely
targets ofMn toxicity such as the dopamin-
ergic nigrostriatal system (31), but it is not
clear whether these methods afford ade-
quate resolution at levels of Mn exposure
relevant to most environmental and occu-
pational exposures levels. Although certain
minimal features ofstudy designs and end
points have been specified by the U.S. EPA
(96) (e.g., respiratory function evaluations
should include flow volume, pressure vol-
ume, diffusing capacity, and ventilation and
breathing mechanics), the responsibility for
developing detailed protocols to achieve the
objectives ofthese studies is expected to be
borne by the Ethyl Corporation, subject to
U.S. EPAapproval.
A fundamental issue that affects the
design ofexperimental health studies is the
species ofMn to which human populations
are exposed and, consequently, to which
laboratory animals are to be exposed for
testing purposes. The form or forms ofpar-
ticulate Mn emitted from combustion of
MMT in gasoline have not been definitively
established to date. U.S. EPA scientists have
expressed concern that the testing protocol
used to sample Mn particles in tailpipe
emissions should indude high enough rates
and frequency ofacceleration to be repre-
sentative ofthe operation ofvehides under
actual conditions. Lower rates ofaccelera-
tion may not generate sufficient pressures to
force some particles through the entire
exhaust system and into the sample collec-
tion device. Another issue is the chemical
reactions and transformations that may
occur in the ambient atmosphere depending
on the form ofMn emitted. The presence of
acids and other compounds in the air could
result in chemical changes in particulate Mn
between the tailpipe where it is emitted and
the nosewhere it is inhaled.
For improvement of the exposure
assessment, the U.S. EPAhas recommended
obtaining personal exposure measurements
using a probabilistic sampling design in
areas where MMT is used in gasoline (96).
At the time this recommendation was made,
Canada was the only country where MMT
was used in unleaded gasoline, and thus it
was presumed that such studies would have
to be conducted in Canada. However it was
recognized that differences between U.S.
and Canadian cities, including meteorology,
traffic density, and the concentration of
MMT in gasoline, would need to be taken
into consideration in the design and inter-
pretation of the studies. A stratified sam-
pling design with particular emphasis on
representation ofthe upper tail ofthe expo-
sure distribution (e.g., through oversam-
pling of high-exposure subgroups) was
recommended. The U.S. EPAalso proposed
that personal exposure monitoring and
ambient monitoring (preferably adjacent to
each subject's residence) be conducted con-
currently. Given seasonal differences in
exposures, sampling during at least two dif-
ferent times or seasons ofthe year was advo-
cated. As in the case ofthe health studies, it
was intended that the Ethyl Corporation
would take responsibility for developing
detailed protocols for such exposure studies,
subject to U.S. EPAapproval.
Although the U.S. EPA and the Ethyl
Corporation have been in communication
on these proposals since 1991, the U.S. EPA
has not yet formally notified Ethyl ofthe
proposed testing requirements. Nevertheless
the Ethyl Corporation funded a significant
personal exposure study in Toronto,
Canada, in 1995, the full results ofwhich
have not yet been made available to the U.S.
EPA. Also, preliminaryanimal studies ofMn
toxicityhave been initiated byEthyl (74).
The Ethyl Corporation has also
indicated an intention to conduct pharma-
cokinetic studies ofMn by oral and inhala-
tion routes in rodents as well as primates.
In 1991 the U.S. EPA included a recom-
mendation to characterize the bioaccumu-
lation ofinhaled Mn, primarily to support
extrapolation from less-than-lifetime, high-
level exposures to lifetime, low-level expo-
sures. Although a bioaccumulation study
would be especially valuable in the design
and interpretation of a less-than-lifetime
primate study, the U.S. EPA assigned a
low priority to route-to-route pharmacoki-
netic studies because it was felt that such
an extrapolation could introduce addi-
tional uncertainty in the derivation ofan
RfC. However, appropriate pharmacoki-
netic studies could provide useful dosimet-
ric data for designing and interpreting
toxicity studies. Such studies would need to
investigate Mn disposition in blood, excreta,
and target tissues such as brain regions,
lung, reproductive organs, liver, and kidney.
These studies should also examine Mn dis-
position in relation to gender and lifestage,
from prenatal to senescence, and consider
different oxidation states ofMn, particularly
the divalent and trivalent forms.
Until the U.S. EPA formally notifies
the Ethyl Corporation ofthe studies to be
conducted under the authority of CAA
Section 211(b), any ofthe above proposals
is subject to change. Even then, as pro-
vided in the F/FA rule (7), the Ethyl
Corporation as well as the public will be
afforded an opportunity to comment on
the required studies proposed by the U.S.
EPA, after which the U.S. EPA may mod-
ify requirements before making them final.
Although the proposed requirements are
more extensive than the standard assays
required under the F/FA rule, they are
designed only to address specific issues
directly relevant to the risk assessment of
Mn in relation to MMT. In this respect
some observers might prefer to characterize
the prescribed studies as testing rather than
research, the latter term perhaps implying a
less prescriptive specification ofobjectives
or methods. In anyevent it is expected that
the study protocols will undergo solicited
peer review to ensure that the studies will
be optimally designed to address key risk
assessment questions and issues. This is not
to say that studies prescribed by the U.S.
EPA are the onlystudies that could provide
information of relevance to assessing the
potential health risks related to MMT. A
better understanding ofthe basic mecha-
nisms ofMn toxicity could be quite help-
ful in interpreting the results of testing
studies. New questions frequently arise
even as testing is conducted, and indepen-
dent investigations outside the focused
program ofstudies to be prescribed by the
U.S. EPA could provevaluable.
Conclusions
The importance ofempirical, quantitative
data on exposure and health effects for
assessing risk is evident in the case of
MMT. Neither assurances of benign or
no detectable effects nor prophesies of
impending catastrophic impacts can be
given much credibility without substan-
tially more information than has been
available to date. Because MMT is already
in use, the need for timelyandwell focused
studies to better characterize the exposures
and health effects resulting from this fuel
additive is all the more important.
Environmental Health Perspectives * Vol 106, Supplement 1 a February 1998 198MNIT: HEALTH RISK UNCERTAINTIES AND RESEARCH DIRECTIONS
REFERENCES
1. ter Haar GL, Lenane DL, Hu JN, Brandt M. Composition,
size and control ofautomotive exhaust particulates. J Air Pollut
Control Assoc 22:39-46 (1972).
2. Piver WT. Potential dilemma: the methods of meeting auto-
motive exhaust emission standards of the Clean Air Act of
1970. Environ Health Perspect 8:165-190 (1974).
3. U.S. Congress. Clean Air ActAmendments of 1977. PL 95-95.
Washington:U.S. Government Printing Office, 1977.
4. Ethyl Corporation. MMT Q & A. Richmond, VA:Ethyl
Corporation, 1997 [Online]. Available from www.ethy.comr
mmtqa.html
5. U.S. Environmental Protection Agency. Fuels and fuel addi-
tives; waiver decision/circuit court remand. Fed Reg
59:42227-42247 (1994).
6. Ethyl Corporation v. the U.S. Environmental Protection
Agency, CA DC, 94-1505, 51 F3d, 1995.
7. U.S. Environmental Protection Agency. Fuels and fuel additives
registration regulations; final rule. Fed Reg 59:33042-33142
(1994).
8. Ethyl Corporation v. the U.S. Environmental Protection
Agency, CA DC, 94-1516, 67 F3d 941, 1995.
9. Urquhart J. Canada's House ofCommons is expected to vote
for ban on ethyl fuel additive. Wall Street J October 28:B6A
(1996).
10. Menkes DB, Fawcett JP. Too easily lead? Health effects of
gasoline additives. Environ Health Perspect 105:270-273
(1997).
11. U.S. Congress. Clean Air Act Amendments of 1990. PL 101-
549. Washington:U.S. Government Printing Office, 1990.
12. Silbergeld EK. Hazards ofmanganese as an additive in vehicle
fuel. In: International Conference: Heavy Metals in the
Environment, Vol 2, September, New Orleans, LA (Lindberg
SE, Hutchinson TC, eds). Edinburgh:CEP Consultants, 1987;1.
13. DavisJM, Elias RW, Grant LD. Efforts to reduce lead exposure
in the United States. In: Mineral and Metal Neurotoxicology
(Yasui M, Strong MJ, Ota K, Verity MA, eds). Boca Raton, FL:
CRC Press, 1996;285-293.
14. Garrison AW, Cipollone MG, Wolfe NL, Swank RR Jr.
Environmental fate ofmethylcyclopentadienyl manganese tri-
carbonyl. Environ Toxicol Chem 14:1859-1864 (1995).
15. U.S. Environmental Protection Agency. (1995, November).
Oral reference dose (RfD) for manganese. In: IRIS (Integrated
Risk Information System) [Database Online]. Available from
www.epa.gov/ngispgm3/iris/index.html
16. Couper J. On the effects ofblack oxide of maganese when
inhaled into the lungs. BrAnn Med Pharm 1:41-42 (1837).
17. Aschner M, Aschner JL. Manganese neurotoxicity: cellular
effects and blood-brain barrier transport. Neurosci Biobehav
Rev 15:333-340 (1991).
18. Murphy VA, Wadhwani KC, Smith QR, Rapoport SI.
Saturable transport ofmanganese(II) across the ratblood-brain
barrier. J Neurochem 57:948-954 (1991).
19. Rabin 0, Hegedus L, Bourre J-M, Smith QR. Rapid brain
uptake of manganese(II) across the blood-brain barrier. J
Neurochem 61:509-517 (1993).
20. Tjalve H, Henriksson J, TallkvistJ, Larsson BS, Lindquist NG.
Uptake of manganese and cadmium from the nasal mucosa
into the central nervous system via olfactory pathways in rats.
Pharmacol Toxicol 79:347-356 (1996).
21. ter Haar GL, Griffing ME, Brandt M, Oberding DG, Kapron
M. Methylcyclopentadienyl manganese tricarbonyl as an anti-
knock: composition and fate ofmanganese exhaust products.
In: 67th Annual Meeting of the Air Pollution Control
Association, 9-13 June, Denver, Colorado. Pittsburgh, PA:Air
Pollution Control Association, 1974.
22. National Research Council. Risk Assessment in the Federal
Government: Managing the Process. Washington:National
Academy Press, 1983.
23. U.S. EPA. Reevaluation ofInhalation Health Risks Associated
with Methylcyclopentadienyl Manganese Tricarbonyl (MMT)
in Gasoline [Final]. EPA/600/R-94/062. Washington:U.S.
Environmental Protection Agency, 1994.
24. Rodier J. Manganese poisoning in Moroccan miners. Br J Ind
Med 12:21-35 (1955).
25. Cotzias GC, Horiuchi K, Fuenzalida S, Mena I. Chronic man-
ganese poisoning: clearance oftissue manganese concentrations
with persistence of the neurological picture. Neurology
18:376-382 (1968).
26. Barbeau A. Etiology ofParkinson's disease: a research strategy.
CanJ Neurol Sci 11:24-28 (1984).
27. Wolters EC. Manganese-induced parkinsonism. In: Mineral
and Metal Neurotoxicology (Yasui M, Strong MJ, Ota K,
Verity MA, eds). Boca Raton, FL:CRC Press, 1996;319-325.
28. Calne DB, Chu N-S, Huang C-C, Lu C-S, Olanow W.
Manganism and idiopathic parknsonism: similarities and dif-
ferences. Neurology44:1583-1586 (1994).
29. Yamada M, Ohno S, Okayasu I, Okeda R, Hatakeyama S,
Watanabe H, Ushio K, Tsukagoshi H. Chronic manganese
poisoning: a neuropathological study with determination of
manganese distribution in the brain. Acta Neuropathol
70:273-278 (1986).
30. Newland MC, Weiss B. Persistent effects of manganese on
effortful responding and their relationship to manganese accu-
mulation in the primate globus pallidus. Toxicol Appl
Pharmacol 113:87-97 (1992).
31. Shinotoh H, Snow BJ, Hewitt KA, Pate BD, Doudet D,
Nugent R, Perl DP, Olanow W, Calne DB. MRI and PET
studies of manganese-intoxicated monkeys. Neurology
45:1199-1204 (1995).
32. Bird ED, Anton AH, Bullock B. The effect of manganese
inhalation on basal ganglia dopamine concentrations in rhesus
monkey. Neurotoxicology 5:59-65 (1984).
33. Eriksson H, TedroffJ,Thuomas K-A, Aquilonius S-M, Hartvig
P, Fasth K-J, Bjurling P, Lngstrom B, Hedstrom K-G,
Heilbronn E. Manganese inducedbrain lesions inMacacafascic-
ularis as revealed by positron emission tomography and mag-
netic resonance imaging. Arch Toxicol 66:403-407 (1992).
34. Heilbronn E, Eriksson H. Implications of manganese in dis-
ease, especially central nervous system disorders. In: Mineral
and Metal Neurotoxicology (Yasui M, Strong MJ, Ota K,
Verity MA, eds). Boca Raton, FL:CRC Press, 1996;311-317.
35. Wolters EC, Huang C-C, Clark C, Peppard RF, OkadaJ, Chu
N-S, Adam MJ, Ruth TJ, Li D, Calne DB. Positron emission
tomography in manganese intoxication. Ann Neurol 26:647-651
(1989).
36. Gavin CE, Gunter KK, Gunter TE. Mn2+ sequestration by
mitochondria and inhibition of oxidative phosphorylation.
ToxicolAppl Pharmacol 115:1-5 (1992).
37. Brouillet EP, Shinobu L, McGarvey U, Hochberg F, Beal MF.
Manganese injection into the rat striatum produces excitotoxic
lesions by impairing energy metabolism. Exp Neurol
120:89-94 (1993).
38. Saric M. Occupational and environmental exposures and non-
specific lung disease-a review ofselected studies. IsrJ Med Sci
28:509-512 (1992).
39. Roels H, Lauwerys R, Buchet J-P, Genet P, Sarhan MJ,
Hanotiau I, de Fays M, Bernard A, Stanescu D.
Epidemiological survey among workers exposed to manganese:
effects on lung, central nervous system, and some biological
indices. AmJ Ind Med 11:307-327 (1987).
40. Nogawa K, Kobayashi E, Sakamoto M, Fukushima N, Ishizaki
A, Makino N, Kagamimori S, Hiramaru Y, Kawano S, Kato T
et al. Studies ofthe effects on the respiratory organs of air pol-
lution consisting ofdusts composed mainly ofmanganese (first
report). Effects on the respiratory organs ofjunior igh school
students. Nippon Koshu Eisei Zasshi 20:315-325 (1973).
Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998 199J.M. DAVIS
41. Cook DG, Fahn S, Brait KA. Chronic manganese intoxication.
Arch Neurol 30:59-64 (1974).
42. Lauwerys R, Roels H, Genet P, Toussaint G, Bouckaert A, De
Cooman S. Fertility ofmale workers exposed to mercury vapor
or to manganese dust: a questionnaire study. Am J Ind Med
7:171-76 (1985).
43. Deskin R, Bursian SJ, Edens FW. The effect ofchronic man-
ganese administration on some neurochemical and physiologi-
cal variables in neonatal rats. Gen Pharmacol 12:279-280
(1981).
44. U.S. Environmental Protection Agency. (1988, September).
CRAVE cancer assessment for manganese. In: IRIS (Integrated
Risk Information System) [Database Online]. Available from
www.epa.gov/ngispgm3/iris/index.ht-mI
45. Roels HA, Ghyselen P, BuchetJP, Ceulemans E, Lauwerys RR.
Assessment ofthe permissible exposure level to manganese in
workers exposed to manganese dioxide dust. Br J Ind Med
49:25-34 (1992).
46. U.S. Environmental Protection Agency (1990, December).
Inhalation reference concentration (RfC) for manganese. In:
IRIS (Integrated Risk Information System) [Database Online].
Available From www.epa.gov.ngispgm3/iris/index.html
47. U.S. Environmental Protection Agency (1993, December).
Inhalation reference concentration (RfC) for manganese. In:
IRIS (Integrated Risk Information System) [Database Online].
Available from www.epa.gov.ngispgm3/iris/index.html
48. Mergler D, Huel G, Bowler R, Iregren A, Belanger S, Baldwin
M, TardifR, Smargiassi A, Martin L. Nervous system dysfunc-
tion among workers with long-term exposure to manganese.
Environ Res 64:151-180 (1994).
49. Iregren A. Psychological test performance in foundry workers
exposed to low levels of manganese. Neurotoxicol Teratol
12:673-675 (1990).
50. Lucchini R, Selis L, Folli D, Apostoli P, Mutti A, Vanoni 0,
Iregren A, Alessio L. Neurobehavioral effects of manganese
in workers from a ferroalloy plant after temporary cessation
of exposure. Scand J Work Environ Health 21:143-149
(1995).
51. American Conference ofGovernmental Industrial Hygienists.
1996 TLVs and BEIs: Threshold Limit Values for Chemical
Substances and Physical Agents and Biological Exposure Indices.
Cincinnati, OH:American Conference of Governmental
Industrial Hygienists, 1992;40-45.
52. Roels H. AttachmentA-1: individual exposure and dichotomized
response data ofRoels (1993). In: Reevaluation ofInhalation
Health Risks Associated with Methylcyclopentadienyl
Manganese Tricarbonyl (MMT) in Gasoline [Final].
EPA/600/R-94/062. Washington:U.S. Environmental
ProtectionAgency, 1994;A-66-A68.
53. Crump KS. A new method for determining allowable daily
intakes. FundamAppl Toxicol 4:854-871 (1984).
54. Hasselblad V, Jarabek AM. Dose-response analysis of toxic
chemicals. In: Bayesian Biostatistics (Berry DA, Stangl DK,
eds). NewYork:Marcel Dekker, 1994;235-259.
55. Davis JM, Jarabek A, Mage DT, Graham JA. The EPA health
risk assessment ofmethylcyclopentadienyl manganese tricar-
bonyl (MMT). RiskAnal (in press).
56. Clayton CA, Perritt RL, Pellizzari ED, Thomas KW, Whitmore
RW, Wallace LA, Ozkaynak H, Spengler JD. Particle total
exposure assessment methodology (PTEAM) study: distribu-
tions of aerosol and elemental concentrations in personal,
indoor, and outdoor air samples in a southern California com-
munity. J Exposure Anal Environ Epidemiol 3:227-250 (1993).
57. Lynam DR, Pfeifer GD, ter Haar GL, Fort BF. Exposures to
manganese-in-air in an urban environment. In: Trace
Substances in Environmental Health: Proceedings of the 27th
Annual Conference of the Society of Environmental
Geochemistry and Health, July 1993, New Orleans, Louisiana
(Cothern, CR, ed). Northwood, United Kingdom:Science
Reviews, 1994;21-29.
58. Zayed J, Gerin M, Loranger S, Sierra P, Begin D, Kennedy G.
Occupational and environmental exposure ofgarage workers
and taxi drivers to airborne manganese arising from the use of
methylcyclopentadienyl manganese tricarbonyl in unleaded
gasoline. Am Ind HygAssocJ 55:53-58 (1994).
59. Kirshenblatt M. Unpublished data.
60. Loranger S, Zayed J, Forget E. Manganese contamination in
Montreal in relation with traffic density. Water Air Soil Pollut
74:385-396 (1994).
61. Lytle CM, Smith BN, McKinnon CZ. Manganese accumula-
tion along Utah roadways: a possible indication ofmotor vehi-
cle exhaust pollution. Sci Total Environ 162:105-109 (1995).
62. Pellizzari ED, Thomas KW, Clayton CA, Whitmore RW,
Shores RC, Zelon HS, Perritt RL. Particle Total Exposure
Assessment Methodology (PTEAM): Riverside, California,
Pilot Study. Vol I [Final Report]. EPA/600/R-93/050.
Research Triangle Park, NC:U.S. Environmental Protection
Agency, 1992.
63. Lonnerdal B. Dietary factors affecting trace element absorption
in infants. Acta Paediatr Scand Suppl 351:109-113 (1989).
64. Fell JME, Reynolds AP, Meadows N, Khan K, Long SG,
Quaghebeur G, Taylor WJ, Milla PJ. Manganese toxicity in
children receiving long-term parenteral nutrition. Lancet
347:1218-1221 (1996).
65. Wilson DC, Tubman R, Bell N, Halliday HL, McMaster D.
Plasma manganese, selenium and glutathione peroxidase levels
in the mother and newborn infant. Early Hum Dev
26:223-226 (1991).
66. Tholin K, Sandstrom B, Palm R, Hallmans G. Changes in
blood manganese levels during pregnancy in iron supplemented
and non supplemented women. J Trace Elem Med Biol
9:13-17 (1995).
67. Kawamura R, Ikuta H, Fukuzumi S, Yamada R, Tsubaki S,
Kodama T, Kurata S. Intoxication by manganese in well water.
Kitasato Arch Exp Med 18:145-169 (1941).
68. Mena I, Horiuchi K, Burke K, Cotzias GC. Chronic man-
ganese poisoning: individual susceptibility and absorption of
iron. Neurology 19:1000-1006 (1969).
69. Davidsson L, Cederblad A, Lonnerdal B, Sandstrom B. The
effect ofindividual dietary components on manganese absorp-
tion in humans. AmJ Clin Nutr 54:1065-1070 (1991).
70. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS,
Olanow CW. Blood manganese correlates with brain magnetic
resonance imaging changes in patients with liver disease. Can J
Neurol Sci 23:95-98 (1996).
71. Krieger D, Krieger S, Jansen 0, Gass P, Theilmann L,
Lichtnecker H. Manganese and chronic hepatic encephalopa-
thy. Lancet 346:270-274 (1995).
72. Davis JM, Grant LD. The sensitivity ofchildren to lead. In:
Similarities and Differences Between Children and Adults:
Implications for Risk Assessment (Guzelian PS, Henry CJ,
Olin SS, eds). Washington:International Life Sciences Institute
Press, 1992;150-162.
73. Soliman EF, Slikker W Jr, Ali SF. Manganese-induced oxida-
tive stress as measured by a fluorescent probe: in vitro study.
Neurosci Res Comm 17:185-193 (1995).
74. Vitarella D, Struve MF, Goetz J, Ledford FI, Miller R,
Dorman DC. Comparative neurotoxicity of oral manganese
(II) chloride in neonatal and adult CD rats. In: 20th Annual
Chemical Industry Institute ofToxicology Scientific Open
House, 8 October, Research Triangle Park, NC. Research
Triangle Park, NC:Chemical Industry Institute ofToxicology,
1996;46-47.
75. Kontur PJ, Fechter LD. Brain regional manganese levels and
monoamine metabolism in manganese-treated neonatal rats.
Neurotoxicol Teratol 10:295-303 (1988).
76. Seth PK, Chandra SV. Neurotransmitters and neurotransmitter
receptors in developing and adult rats during manganese poi-
soning. Neurotoxicology 5:67-76 (1984).
77. Cotzias GC, Miller ST, Papavasiliou PS, Tang LC. Interactions
between manganese and brain dopamine. Med Clin North Am
60:729-738 (1976).
78. Bell JG, Keen CL, Lonnerdal B. Higher retention of man-
ganese in suckling than in adult rats is not due to maturational
200 Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998MMT: HEALTH RISK UNCERTAINTIES AND RESEARCH DIRECTIONS
differences in manganese uptake by rat small intestine. J
Toxicol Environ Health 26:387-398 (1989).
79. Mena I. Manganese. In: Disorders of Mineral Metabolism
(Bronner F, Coburn JW, eds). New York:Academic Press,
1981;233-270.
80. Dawson R Jr, Beal MF, Bondy SC, Di Monte DA, Isom GE.
Excitotoxins, aging, and environmental neurotoxins: implica-
tions for understanding human neurodegenerative diseases.
Toxicol AppI Pharmacol 134:1-17 (1995).
81. Desole MS, Esposito G, Migheli R, Fresu L, Sircana S, Zangani
D, Miele M, Miele E. Cellular defence mechanisms in the stria-
tum ofyoung and aged rats subchronically exposed to man-
ganese. Netiropharmacology 34:289-295 (1995).
82. Weiss B, Reuhl K. Delayed neurotoxicity: a silent toxicity. In:
.-Leurological Disease and Therapy. Vol 26: Principles of
Neurotoxicology (Chang LW, ed). New York:Marcel Dekker,
1994;765-784.
83. Wennberg A. Neurotoxic effects ofselected metals. Scand J
Work Environ Health 20(Special Issue):65-71 (1994).
84. Smyth LT, Ruhf RC, Whitman NE, Dugan T. Clinical man-
ganism and exposure to manganese in the production and pro-
cessing offerromanganese alloy. J Occup Med 15:101-109
(1973).
85. Lown BA, Morganti JB, D'Agostino R, Stineman CH, Massaro
EJ. Effects on the postnatal development ofthe mouse ofpre-
conception, postconception and/or suckling exposure to man-
ganese via maternal inhalation exposure to MnO2 dust.
Neurotoxicology 5:119-131 (1984).
86. Archibald FS, Tyree C. Manganese poisoning and the attack of
trivalent manganese upon catecholamines. Arch Biochem
Biophys 256:638-650 (1987).
87. Donaldson J, McGregor D, LaBella F. Manganese neurotoxic-
ity: a model for free radical mediated neurodegeneration? Can J
Physiol Pharmacol 60:1398-1405 (1982).
88. Ali SF, Duhart HM, Newport GD, Lipe GW, Slikker W Jr.
Manganese-induced reactive oxygen species: comparison
between Mn+2 and Mn+3. Neurodegeneration 4:329-334
(1995).
89. Oberdoerster G, Cherian G. Manganese. In: Biological
Monitoring of Toxic Metals (Clarkson TW, Friber L,
Nordberg GF, Sager PR, eds). New York:Plenum Press,
1988;283-301.
90. Drown DB, Oberg SG, Sharma RP. Pulmonary clearance of
soluble and insoluble forms of manganese. J Toxicol Environ
Health 17:201-212 (1986).
91. Komura J, Sakamoto M. Subcellular and gel chromatographic
distribution of manganese in the mouse brain: relation to the
chemical form ofchronically-ingested manganese. Toxicol Lett
66:287-294 (1993).
92. Roels H, Meiers G, Delos M, Ortega I, Lauwerys R, BuchetJP,
Lison D. Influence of the route of administration and the
chemical form (MnCI2, MnO2) on the absorption and cerebral
distribution of manganese in rats. Arch Toxicol 71:223-230
(1997).
93. U.S. EPA. ORD's Response to Public Comments on Health
and Exposure Issues in Relation to the Waiver Petition ofEthyl
Corporation to Add Methylcyclopentadienyl Manganese
Tricarbonyl (MMT) to Unleaded Gasoline. Washington:U.S.
Environmental Protection Agency, 1994.
94. Gottschalk LA, Rebello T, Buchsbaum MS, Tucker HG,
Hodges EL. Abnormalities in hair trace elements as indicators
ofaberrant behavior. Compr Psychiatry 32:229-237 (1991).
95. U.S. EPA. Summary of Workshop Discussions at the
Manganese and Methylcyclopentadienyl Manganese
Tricarbonyl (MMT) Conference, 12-15 March, Washington.
Washington:U.S. Environmental Protection Agency, 1991.
96. U.S. EPA. Information Needed to Improve the Risk
Characterization of Manganese Tetraoxide (Mn304) and
Methylcyclopentadienyl Manganese Tricarbonyl (MMT).
Washington:U.S. Environmental Protection Agency, 1991.
97. Shiotsuka RN. Inhalation toxicity ofmanganese dioxide and a
magnesium oxide-manganese dioxide mixture. Army Project
Order No 3803. Frederick, MD:U.S. Army Medical Research
and Development Command, 1984.
98. Moore W, Hysell D, Miller R, Malanchuk M, Hinners R,
Yang Y, Stara JF. Exposure of laboratory animals to atmos-
pheric manganese from automotive emissions. Environ Res
9:274-284 (1975).
99. Lloyd Davies TA, Harding HE. Manganese pneumonitis: fur-
ther clinical and experimental observations. Br J Ind Med
6:82-90 (1949).
100. Nishiyama K, Suzuki Y, Fujii N, Yano H, Miyai T, Ohmishi
K. Effect of long-term inhalation of manganese dusts. II:
Continuous observation of the respiratory organs of monkeys
and mice. Nihon Eiseigaku Zasshi 30:117 (1975).
101. Laskey JW, Rehnberg GL, Hein JF, Carter SD. Effects of
chronic manganese (Mn304) exposure on selected reproductive
parameters in rats. J Toxicol Environ Health 9:677-687
(1982).
102. Morganti JB, Lown BA, Stineman CH, D'Agostino RB,
Massaro EJ. Uptake, distribution and behavioral effects of
inhalation exposure to manganese (MnO2) in the adult mouse.
Neurotoxicology 6:1-16 (1985).
103. Suzuki Y, Fujii N, Yano H, Ohkita T, Ichikawa A, Nishiyama
K. Effects ofthe inhalation ofmanganese dioxide dust on mon-
key lungs. TokushimaJ Exp Med 25:119-125.
104. Eriksson H, Magiste K, Plantin L-O, Fonnum F, Hedstrom K-
G, Theodorsson-Norheim E, Kristensson K, Stalberg E,
Heilbronn E. Effects of manganese oxide on monkeys as
revealed by a combined neurochemical, histological and neuro-
physiological evaluation. Arch Toxicol 61:46-52 (1987).
105. Roels H, Lauwerys R, Genet P, Sarhan MJ, de Fays M,
Hanotiau I, Buchet J-P. Relationship between external and
internal parameters ofexposure to manganese in workers from
a manganese oxide and salt producing plant. Am J Ind Med
11:297-305 (1987).
106. Gerhardsson L, Skerfving S. Concepts on biological markers
and biomonitoring for metal toxicity. In: Toxicology ofMetals
(Chang LW, Magos L, Suzuki T, eds). Boca Raton, FL:CRC
Lewis, 1996;81-107.
Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998 201